George Coukos
@CoukosGeorge
Followers
934
Following
58
Media
1
Statuses
48
Obsessed about T cells, quality, truth, hard work - aiming for the cure
Lausanne, Switzerland
Joined August 2021
Had a great time meeting all the colleagues and friends at @GustaveRoussy! Thanks for the great day!
π Thanks to all the participants and Pr. @CoukosGeorge for todayβs insightful discussion on 'Learning from natural immunity to create synthetic immunity'. Stay tuned for our upcoming event w/ Mark Levis from @HopkinsMedicine in September! #CancerResearchLectures
0
0
25
May is National Cancer Research Month. George Coukos, MD, PhD, a Fellow of the AACR Academy, is one of the 54,000 AACR members who is Bringing Cancer Research to Life. #NCRM23 #ResearchSavesLives #AACRFellows @CoukosGeorge
0
3
12
Thanks Ben! We appreciate your endorsement.
Can a gene edit overcome exhaustion? 𧬠Here @CoukosGeorge show that IL2v/IL33 engineered T cells reverse TIL dysfunction. π https://t.co/VYc5MF1mun Strong work from @CHUVLausanne! π¨π
0
0
8
Delighted to share our newest work on engineering superior effector T states. A new horizon for T cell therapy. Big thanks to Jesus Corria and all the colleagues at Ludwig.
George Coukos and colleagues show that orthogonal cytokine engineering can reprogram CD8 T cells to escape exhaustion leading to tumor regression. Read it here: https://t.co/ToyXbu672u
@CorriaJesus @CoukosGeorge
https://t.co/rsmwukHHuD
3
12
91
George Coukos and colleagues show that orthogonal cytokine engineering can reprogram CD8 T cells to escape exhaustion leading to tumor regression. Read it here: https://t.co/ToyXbu672u
@CorriaJesus @CoukosGeorge
https://t.co/rsmwukHHuD
0
20
48
As we ring out 2022, we wish a very happy holiday season & New Year to all our partners, supporters and followers of the academic #CancerResearch community @unil @CHUVLausanne @Ludwig_Cancer.
0
2
18
Our report, Women in science: Perspectives from Ludwig leaders, profiles eight remarkable women affiliated with Ludwig Cancer Research. We'll be posting their stories individually here over the next several days. The whole report: https://t.co/e4pdjiKYQ1
#LudwigWomenLeaders
2
25
35
Congrats Sohrab, Dmitry and team. Amazing work.
Very proud to have been part of this amazing team effort with @SohrabShah and MSK GYN team. Thank you @CoukosGeorge for an amazing summary in
0
0
1
Just out in @NatureNV, @CoukosGeorge and Denarda Dangaj Laniti consider how data that reveal cellular, molecular and mutational landscape, as ovarian cancer tumours grow and spread, might aid efforts to develop new targeted therapies. @unil @chuv @Ludwig_Cancer
0
4
17
New #JITC commentary: Patient-reported outcomes in adoptive cell-therapy trials: mind the gap https://t.co/oJpNKPx6D8
@EleonoraGhisoni @MMorotti @CoukosGeorge @sacola00 @MassimoDiMaio75
0
5
21
TIL Therapy Entering the Mainstream https://t.co/9gREglXpny Delighted to have contributed this editorial. An important step forward for TIL therapy. Congrats to the NKI and Herlev H teams of John Haanen and Inge-Marie Svane. And a big thanks to Steve Rosenberg and colleagues!
pubmed.ncbi.nlm.nih.gov
TIL Therapy Entering the Mainstream
1
9
67
Another great panel discussion at #ESMOImmuno22 / @QuezadaLab @CoukosGeorge @BcellBruno @CoffmanLab /differences between #ovarian & #fallopian tube #cancers (FT has more #TLS per Dr Coffman)/questions from @DeRieneke & many more/HEV 1 marker u need 2 define TLS
0
1
8
Read also the News & Views article on the study by @CoukosGeorge, Yaquelin Ortiz-Miranda and Melita Irving: PDF: https://t.co/I7kprWmqde
https://t.co/V0QKouWY5r
0
7
12
A commentary by @CoukosGeorge, Yaquelin Ortiz-Miranda and @IrvingMelita -- on @UTSWNews π©πππ ππ ππ.'s study, both just out @NatureCellBio. π https://t.co/f5f9KjaFZ1
@unil @CHUVLausanne @Ludwig_Cancer
0
5
10
DAY3β£ #ASCO22
@CD_AACR @OncoAlert π¨ FINAL5β£papers presented by @ElizSMcKenna π«NO PAY WALL𧱠https://t.co/FchxNwm2hC
@GustaveRoussy @institut_curie @janeway_MD @Albert0Bardelli @fg_herrera @melitairving @weoncologists @CoukosGeorge @OncoUNILCHUV @Ludwig_Cancer @CHUVLausanne
1
13
21
Delighted to share our paper, https://t.co/iQ9SmKyLRM . Huge thanks to @CoukosGeorge for the opportunity as well as all our collaborators, @carmonation. A summary of our main findings:
biorxiv.org
Adoptive immunotherapy offers opportunities to reprogram T cells and the tumor microenvironment. Orthogonal engineering of adoptively transferred T cells with an IL-2RΞ²Ξ³-binding IL-2 variant,...
3
11
38
@CoukosGeorge @Ludwig_Cancer @OncoUNILCHUV A summary of our main Findings 1-Orthogonal combinatorial T-cell engineering overcomes homeostatic barriers to engraftment, reprograms TILs as well as the tumor microenvironment and mediates solid tumor regression in the absence of preconditioning or systemic cytokine support.
0
2
5
Delighted to share our new synthetic T cell states achieved by orthogonal engineering. Super effector T cells escaping #exhaustion for next-gen #immunotherapy! A big thanks to @corriaJesus and the highly talented team at @Ludwig_Cancer @OncoUNILCHUV
https://t.co/YXvgzLSWKe
biorxiv.org
Adoptive immunotherapy offers opportunities to reprogram T cells and the tumor microenvironment. Orthogonal engineering of adoptively transferred T cells with an IL-2RΞ²Ξ³-binding IL-2 variant,...
14
22
136
JOB ALERT #Switzerland #bioinformatics #immunooncology #singlecell Please RT! We are looking for a computational biologist (Postdoc/PhD) to join our team at @unil @ISBSIB @Ludwig_Cancer @OncoUNILCHUV to develop single-cell methods for precision IO Job ad soon, please DM for +info
1
86
123
New #JITC article: Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma https://t.co/NsnBwVeeB8
@michal_bassani @CoukosGeorge
0
7
13